StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.24−0.16 (-6.67%)

Close on Nov 16, 2026Market cap $5.06MP/E –Yield –

Biodexa Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Biodexa Pharmaceuticals's total assets was £12.72M at Jun 30, 2026. For fiscal 2025 it was £18.18M, up 23.0% from the year before. Over ten years it grew -11.8% a year on average. The highest annual figure on record is £64.04M in fiscal 2015.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025£18.18M+23.0%
FY2024Dec 31, 2024£14.78M+40.2%
FY2023Dec 31, 2023£10.54M+90.8%
FY2022Dec 31, 2022£5.53M-57.2%
FY2021Dec 31, 2021£12.91M+31.5%
FY2020Dec 31, 2020£9.82M-68.2%
FY2019Dec 31, 2019£30.90M+51.1%
FY2018Dec 31, 2018£20.44M-58.5%
FY2017Dec 31, 2017£49.22M-13.2%
FY2016Dec 31, 2016£56.69M-11.5%
FY2015Dec 31, 2015£64.04M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026£12.72M-8.9%
Q4 FY2025Dec 31, 2025£18.18M+72.4%
Q2 FY2025Jun 30, 2025£14.82M+86.2%
Q4 FY2024Dec 31, 2024£14.78M+167.5%
Q2 FY2024Jun 30, 2024£13.97M+8.2%
Q4 FY2023Dec 31, 2023£10.54M+7.4%
Q2 FY2023Jun 30, 2023£7.96M-74.2%
Q4 FY2022Dec 31, 2022£5.53M-73.0%
Q4 FY2021Dec 31, 2021£12.91M-73.8%
Q4 FY2020Dec 31, 2020£9.82M-82.7%
Q4 FY2019Dec 31, 2019£30.90M-51.8%
Q4 FY2018Dec 31, 2018£20.44M–
Q4 FY2017Dec 31, 2017£49.22M–
Q4 FY2016Dec 31, 2016£56.69M–
Q4 FY2015Dec 31, 2015£64.04M–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?